The Asia Pacific endothelial dysfunction market is expected to grow from US$ 304.48 million in 2022 to US$ 405.51 million by 2028. It is estimated to grow at a CAGR of 4.9% from 2022 to 2028.
Rising Usage of Novel Biomarkers and Therapeutic Strategies Fuels Asia Pacific Endothelial Dysfunction Market
Examining endothelial function can improve risk stratification, improve early disease detection, and assess vascular response to therapeutic interventions. There are studies to understand the pathophysiological mechanisms underlying endothelial dysfunction and atherosclerosis progression in a better way and identify new biomarkers and therapeutic strategies to prevent endothelial dysfunction and atherosclerosis to reduce the risk of developing coronary artery disease (CAD) and related complications. Using liquid biopsies and new molecular biology techniques has enabled the identification of a growing list of molecular and cellular markers of endothelial dysfunction that have provided insight into the molecular basis of atherosclerosis as well as potential biomarkers and therapeutic targets for the prevention and treatment of atherosclerosis and CAD.
Research on biomarkers and their clinical application has increased exponentially over the last few decades. Invaluable insight into the pathophysiology of atherosclerosis and the development of novel therapies have been provided by systemic biomarkers. Endothelial dysfunction and inflammation play a central role in the development and progression of CAD. Inflammatory mediators are secreted by inflammatory and vascular cells in atherosclerotic plaque or by organs such as the liver or adipose tissue.
Asia Pacific Endothelial Dysfunction Market Overview
The endothelial dysfunction market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The growth of the market in the region is attributed to the increasing cases of endothelial dysfunction with the rising incidence of CVD, hypertension, diabetes, and chronic diseases, coupled with the growing aging population. In addition, the market is driven by increasing investments in diagnostics techniques by the respective country governments, resulting in advancements in diagnostics methods.
Asia Pacific Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Asia Pacific Endothelial Dysfunction Market Segmentation
The Asia Pacific endothelial dysfunction market is segmented into cause, test type, end user, and country.
Based on cause, the Asia Pacific endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, Behcet's disease, and others. The hypertension segment registered the largest Asia Pacific endothelial dysfunction market share in 2022.
Based on test type, the Asia Pacific endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held a larger Asia Pacific endothelial dysfunction market share in 2022. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.
Based on end user, the Asia Pacific endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held the largest Asia Pacific endothelial dysfunction market share in 2022.
Based on country, the Asia Pacific endothelial dysfunction market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific endothelial dysfunction market in 2022.
ZOLL Medical Corp, Sphingo Tec GmbH, Perimed AB, and Medizinische Messtechnik GmbH are some of the leading companies operating in the endothelial dysfunction market in the region.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 304.48 Million |
| Market Size by 2028 | US$ 405.51 Million |
| CAGR (2022 - 2028) | 4.9% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Cause
|
|
Regions and Countries Covered
|
|
| Asia-Pacific | China, India, Japan, Australia, Rest of Asia-Pacific |
| Market leaders and key company profiles |
|
1. Medizinische Messtechnik GmbH
2. Perimed AB
3. Sphingo Tec GmbH
4. ZOLL Medical Corp
The Asia Pacific Endothelial Dysfunction Market is valued at US$ 304.48 Million in 2022, it is projected to reach US$ 405.51 Million by 2028.
As per our report Asia Pacific Endothelial Dysfunction Market, the market size is valued at US$ 304.48 Million in 2022, projecting it to reach US$ 405.51 Million by 2028. This translates to a CAGR of approximately 4.9% during the forecast period.
The Asia Pacific Endothelial Dysfunction Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Endothelial Dysfunction Market report:
The Asia Pacific Endothelial Dysfunction Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Endothelial Dysfunction Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Endothelial Dysfunction Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Endothelial Dysfunction Market
